Karen L. Smith

Insider Reports History

Entity
Individual
Location
C/O Jazz Pharmaceuticals Plc, 5 Th Fl, Waterloo Exchange, Waterloo Rd, Dublin L2 4, Ireland
Signature
/s/ Kaitlyn Arsenault, as Attorney-in-Fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Karen L. Smith:

Stock Role Class Num Shares Value Price $ Report Date Ownership
SANGAMO THERAPEUTICS, INC Director Common Stock 77.1K $46.3K $0.60 Jun 4, 2024 Direct
Emergent BioSolutions Inc. EVP, Chief Medical Officer Common Stock 11.9K $21.6K $1.82 May 7, 2021 Direct
Quince Therapeutics, Inc. Chief Medical Officer Employee Stock Option (right to buy) 225K Feb 1, 2023 Direct
Skye Bioscience, Inc. Director Stock Option (Right to Buy) 70K Oct 28, 2024 Direct
SANGAMO THERAPEUTICS, INC Director Stock Option (Right to Buy) 50K Jun 4, 2024 Direct
Skye Bioscience, Inc. Director Director Stock Option (Right to Buy) 40K Jul 2, 2024 Direct
Aurinia Pharmaceuticals Inc. Director Stock Option (right to buy) 29K Aug 18, 2023 Direct
Talaris Therapeutics, Inc. Director Stock Option (Right to Buy) 20.5K Jun 13, 2023 Direct
Context Therapeutics Inc. Director Stock Option (right to buy) 19.3K Sep 4, 2024 Direct
Aurinia Pharmaceuticals Inc. Director Restricted Stock Units 17.9K Aug 18, 2023 Direct
ACCELERON PHARMA INC Director Common Stock 0 $29.37 Nov 19, 2021 Direct
ACCELERON PHARMA INC Director Option to Purchase Common Stock 0 Nov 19, 2021 Direct
ANTARES PHARMA, INC. Director Common Stock 0 $5.60 May 24, 2022 Direct
ANTARES PHARMA, INC. Director Stock Option (right to buy) 0 May 24, 2022 Direct

Insider Reports Filed by Karen L. Smith

Symbol Company Period Transactions Value $ Form Type Date Filed Role
SKYE Skye Bioscience, Inc. Oct 28, 2024 1 $0 4 Oct 30, 2024 Director
CNTX Context Therapeutics Inc. Sep 4, 2024 1 $0 4 Sep 5, 2024 Director
CNTX Context Therapeutics Inc. Sep 4, 2024 0 $0 3 Sep 5, 2024 Director
SKYE Skye Bioscience, Inc. Jul 2, 2024 1 $0 4 Jul 5, 2024 Director
SKYE Skye Bioscience, Inc. Jul 2, 2024 0 $0 3 Jul 5, 2024 Director
SGMO SANGAMO THERAPEUTICS, INC Jun 4, 2024 2 $0 4 Jun 6, 2024 Director
AUPH Aurinia Pharmaceuticals Inc. Aug 18, 2023 2 $0 4 Aug 21, 2023 Director
AUPH Aurinia Pharmaceuticals Inc. Aug 18, 2023 0 $0 3 Aug 21, 2023 Director
TALS Talaris Therapeutics, Inc. Jun 13, 2023 1 $0 4 Jun 14, 2023 Director
SGMO SANGAMO THERAPEUTICS, INC Jun 1, 2023 2 $0 4 Jun 5, 2023 Director
QNCX Quince Therapeutics, Inc. Feb 1, 2023 1 $0 4 Feb 2, 2023 Chief Medical Officer
TALS Talaris Therapeutics, Inc. Jun 9, 2022 1 $0 4 Jun 13, 2022 Director
ATRS ANTARES PHARMA, INC. May 24, 2022 6 -$446K 4 May 26, 2022 Director
QNCX Cortexyme, Inc. May 19, 2022 1 $0 4/A May 27, 2022 Chief Medical Officer
QNCX Cortexyme, Inc. May 19, 2022 0 $0 3 May 23, 2022 Chief Medical Officer
TALS Talaris Therapeutics, Inc. May 16, 2022 1 $0 4 May 17, 2022 Director
TALS Talaris Therapeutics, Inc. May 16, 2022 0 $0 3 May 17, 2022 Director
SGMO SANGAMO THERAPEUTICS, INC Feb 25, 2022 2 $0 4 Mar 1, 2022 Director
XLRN ACCELERON PHARMA INC Nov 19, 2021 6 $0 4 Nov 22, 2021 Director
ATRS ANTARES PHARMA, INC. Jun 10, 2021 2 $112K 4 Jun 14, 2021 Director
EBS Emergent BioSolutions Inc. May 7, 2021 1 -$18.6K 4 May 11, 2021 EVP, Chief Medical Officer